File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies

TitleEZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
Authors
Issue Date2011
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2011, v. 60 n. 7, p. 967-976 How to Cite?
Abstract
Background and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.
Persistent Identifierhttp://hdl.handle.net/10722/137272
ISSN
2013 Impact Factor: 13.319
ISI Accession Number ID
Funding AgencyGrant Number
China's 973 National Basic Research Programme2010CB529401
2010CB912803
863 High Technology Development Programme2007AA021901
Guangzhou Science and Technology Bureau Foundation2005Z1-E0131
Funding Information:

This study was supported by grants made under China's 973 National Basic Research Programme (Nos. 2010CB529401 and 2010CB912803) and 863 High Technology Development Programme (No. 2007AA021901), and by a grant from the Guangzhou Science and Technology Bureau Foundation (No. 2005Z1-E0131).

References

 

DC FieldValueLanguage
dc.contributor.authorCai, MYen_HK
dc.contributor.authorTong, ZTen_HK
dc.contributor.authorZheng, Fen_HK
dc.contributor.authorLiao, YJen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorRao, HLen_HK
dc.contributor.authorChen, YCen_HK
dc.contributor.authorWu, QLen_HK
dc.contributor.authorLiu, YHen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorLin, MCen_HK
dc.contributor.authorZeng, YXen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorXie, Den_HK
dc.date.accessioned2011-08-26T14:22:15Z-
dc.date.available2011-08-26T14:22:15Z-
dc.date.issued2011en_HK
dc.identifier.citationGut, 2011, v. 60 n. 7, p. 967-976en_HK
dc.identifier.issn0017-5749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137272-
dc.description.abstractBackground and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.en_HK
dc.languageengen_US
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_HK
dc.relation.ispartofGuten_HK
dc.rightsGut. Copyright © BMJ Publishing Group.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshCarcinoma, Hepatocellular - diagnosis - pathology-
dc.subject.meshDNA-Binding Proteins - metabolism-
dc.subject.meshLiver Neoplasms - diagnosis - pathology-
dc.subject.meshTranscription Factors - metabolism-
dc.subject.meshTumor Markers, Biological - metabolism-
dc.titleEZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsiesen_HK
dc.typeArticleen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.emailLin, MC:mcllin@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.identifier.authorityLin, MC=rp00746en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1136/gut.2010.231993en_HK
dc.identifier.pmid21330577en_HK
dc.identifier.scopuseid_2-s2.0-79958219307en_HK
dc.identifier.hkuros190887en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79958219307&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume60en_HK
dc.identifier.issue7en_HK
dc.identifier.spage967en_HK
dc.identifier.epage976en_HK
dc.identifier.isiWOS:000291306900016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCai, MY=23388510500en_HK
dc.identifier.scopusauthoridTong, ZT=36747652800en_HK
dc.identifier.scopusauthoridZheng, F=39462354900en_HK
dc.identifier.scopusauthoridLiao, YJ=36114448500en_HK
dc.identifier.scopusauthoridWang, Y=51161989600en_HK
dc.identifier.scopusauthoridRao, HL=35277843000en_HK
dc.identifier.scopusauthoridChen, YC=7601431852en_HK
dc.identifier.scopusauthoridWu, QL=7404602639en_HK
dc.identifier.scopusauthoridLiu, YH=36014503900en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridLin, MC=7404816359en_HK
dc.identifier.scopusauthoridZeng, YX=7402981579en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats